Lijun International Pharmaceutical (Holding) Co. Ltd.

From Wikipedia, the free encyclopedia

Lijun International Pharmaceutical (Holding) Co., Limited (simplified Chinese: 利君国际医药(控股)有限公司; traditional Chinese: 利君國際醫藥(控股)有限公司) (SEHK: 2005) is a Wanchai, Hong Kong-based investment holding company with two pharmaceutical business segments:

Business segments[]

The Group was listed on Hong Kong Stock Exchange in December 2005 (stock code: 2005).

The Group is engaged in the research, development, manufacturing and selling of a wide range of finished medicines and bulk pharmaceutical products to hospitals and distributors, including antibiotics, intravenous infusion solution, non-antibiotics finished products, bulk pharmaceuticals and health care product.

Subsidiaries[]

The Company’s subsidiaries include:

  • New Orient Limited (New Orient) in Hong Kong
  • Shijiazhuang No. 4 Pharmaceutical Co., Limited, intravenous infusion solution manufacturer in Hebei Province (acquired in June 2007)
  • Xi’an Lijun Pharmaceutical Co., Limited (Xi’an Lijun), engaged in manufacturing pharmaceuticals in Shaanxi Province
  • Shenzhen Lijun Pharmaceutical Co., Limited, engaged in manufacturing pharmaceuticals in Guangdong Province.

The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market.

Facing more merger and acquisition opportunities from medical reform in China, the Group is positioned for continuous mergers and acquisitions to promote its growth.

External links[]

Retrieved from ""